Physician profile
Scott Michael Blore
NPI 1063405710
$4,175.54
in general payments reported to CMS, 2019-2025
32 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $322 · 2021: $567 · 2022: $678 · 2023: $933 · 2024: $629 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.50 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $638.43 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $600.39 | 2019-2025 | Vraylar, Ubrelvy, Viberzi |
| Pfizer INC. | $395.30 | 2019-2025 | |
| Amgen INC. | $358.92 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $331.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $253.83 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $213.05 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $166.35 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $140.40 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $105.92 | 2021-2025 | Injectafer |
| Astellas Pharma US INC | $97.28 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $89.86 | 2019-2023 | Gardasil 9, Vaxelis, Proquad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.91 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $73.43 | 2019-2025 | |
| Vbi Vaccine (Delaware) INC. | $66.49 | 2022-2023 | Prehevbrio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56.95 | 2019-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $47.87 | 2022-2024 | Ultomiris |
| Allergan, INC. | $46.68 | 2020 | |
| Lundbeck LLC | $46.39 | 2022-2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $37.12 | 2021 | |
| Sanofi Pasteur INC. | $36.26 | 2019 | |
| Almatica Pharma LLC | $35.90 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.30 | 2022 | |
| Philips North America LLC | $34.06 | 2022 | |
| Esperion Therapeutics, INC. | $32.20 | 2021 | |
| Corcept Therapeutics | $29.94 | 2023 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $29.63 | 2021-2024 | Eliquis |
| Inspire Medical Systems, INC. | $24.77 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.88 | 2025 | Xifaxan |
| Harmony Biosciences LLC | $18.92 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.26 | 2020 | |
| Amarin Pharma, INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Blore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.